AI-first · Genetic algorithms · Alt-data

Bred for superperformance.

Bivid combines AI, alternative data and massive-scale genetic algorithms to generate high-performing, adaptive, systematic trading strategies. We are building quietly. Leave your email and we will be in touch.

You're on the list. We'll be in touch.

No spam, ever.

The vision

A machine that breeds supertraders.

Markets are the hardest competition on earth, and for fifty years the edge went to those with the best quants. We think the next edge goes to whoever can run the largest and smartest evolution. Not a static strategy hand-tuned by a human: tens of thousands of trading genomes per generation today, hundreds of thousands soon, each one adapting as it trades.

Three curves make this possible now and not before. Compute that keeps doubling, so every year the same budget buys a larger evolution. Alternative data that has only just become tradeable and that few incumbents have wired into their strategies. And AI at every layer, making traders smarter and more agile — so the platform gets sharper every time the underlying models do.

Put them together and you get a machine that gets better on its own schedule, not ours. The library of evolved strategies deepens with every run, and the traders it produces are better than the last. That is the play: not a single strategy, but an engine that keeps producing them.

The engine

Born of combat. Constantly improving.

evolved strategy benchmark Illustrative — shape only, not a track record.

Every trader Bivid runs was born in a fight. Tens of thousands of genomes per generation compete, losers are culled, and winners earn their place only on data they have never seen. What survives is a strategy that could not be killed.

Once live, these super-traders can also shape-shift based on signals from regime-sensing AI, drawing on a growing catalog of thousands of evolved plays. This combination of strength and agility is what we believe unlocks superperformance across all asset classes.

Our strategy is long-only, fully collateralized, multi-asset and highly focused on capital preservation. Our best genome is currently beating the market benchmark by 7x — but that's just the start of our superperformance.

Curious? Reach out for a discussion.